Abstract

of Developmental Projects Program (DRP) To ensure a continual renewal of high-quality scientific endeavors in the DF/HCC Kidney Cancer SPORE and to fund efforts that will complement or enhance the overall quality of the DF/HCC Kidney Cancer SPORE. In general, the DRP has funded established investigators. Based on our review, we will be mindful of including more junior investigators. This Program will rely on the infrastructure created by the Administrative, Evaluation, and Planning Core (Admin Core) to: 1. Solicit applications and/or identify novel kidney cancer research projects. 2. Evaluate these projects for funding. 3. Fund innovative developmental projects. 4. Re-evaluate projects for possible transition into full project status. 5. Evaluate the success of the program.

Public Health Relevance

The Developmental Research Program of the DF/HCC Kidney Cancer Program is intended to attract established investigators to the field of kidney cancer in order to develop new ideas of investigation which may change the field or be developed into full projects in the SPORE

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA101942-16
Application #
10024144
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
16
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Scelo, Ghislaine; Muller, David C; Riboli, Elio et al. (2018) KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res 24:5594-5601
Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95
Gao, Xin; Jegede, Opeyemi; Gray, Connor et al. (2018) Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 16:341-348
Liu, Wenjing; Chen, Binbin; Wang, Yang et al. (2018) RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc Natl Acad Sci U S A 115:E1475-E1484
Iorgulescu, J Bryan; Braun, David; Oliveira, Giacomo et al. (2018) Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med 10:87
Gopal, Raj K; Kübler, Kirsten; Calvo, Sarah E et al. (2018) Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell 34:242-255.e5
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Signoretti, Sabina; Flaifel, Abdallah; Chen, Ying-Bei et al. (2018) Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol :JCO2018792259
Hamieh, Lana; Choueiri, Toni K; Ogórek, Barbara et al. (2018) Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet 14:e1007679
Gao, Xin; McDermott, David F (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Biol Ther 18:947-957

Showing the most recent 10 out of 153 publications